Use of Leukocyte-rich and Platelet-rich Fibrin (L-PRF) Adjunct to Surgical Debridement in the Treatment of Stage 2 and 3 Medication-Related Osteonecrosis of the Jaw

dc.authoridCakir, Merve/0000-0002-4340-0309
dc.authoridYalcin, Gul Merve/0000-0002-7438-5834
dc.authorscopusid57192192045
dc.authorscopusid25421095500
dc.authorscopusid58248652400
dc.authorscopusid57044331300
dc.authorscopusid56568277100
dc.authorwosidCakir, Merve/JAA-9861-2023
dc.contributor.authorYalcin-Ulker, Gul Merve
dc.contributor.authorÇakır, Merve
dc.contributor.authorYalçın Ülker, Gül Merve
dc.contributor.authorMeral, Deniz Gökçe
dc.contributor.authorMeral, Deniz Gokce
dc.contributor.otherAğız,Diş ve Çene Cerrahisi / Oral, Dental and Maxillofacial Surgery
dc.date.accessioned2024-05-25T11:37:59Z
dc.date.available2024-05-25T11:37:59Z
dc.date.issued2023
dc.departmentOkan Universityen_US
dc.department-temp[Yalcin-Ulker, Gul Merve; Cakir, Merve; Meral, Deniz Gokce] Istanbul Okan Univ, Fac Dent, Oral & Maxillofacial Surg Dept, Istanbul, Turkiye; [Duygu, Gonca] Tekirdag Namik Kemal Univ, Fac Dent, Oral & Maxillofacial Surg Dept, Tekirdag, Turkiye; [Tanan, Gamze] Trakya Univ, Fac Dent, Oral & Maxillofacial Surg Dept, Edirne, Turkiye; [Yalcin-Ulker, Gul Merve] Istanbul Okan Univ, Fac Dent, Oral & Maxillofacial Surg Dept, TR-34947 Istanbul, Turkiyeen_US
dc.descriptionCakir, Merve/0000-0002-4340-0309; Yalcin, Gul Merve/0000-0002-7438-5834en_US
dc.description.abstractMedication-related osteonecrosis of the jaw (MRONJ) is characterized by exposed necrotic bone persisting for more than 8 weeks in the maxillofacial region in patients using antiresorptive or antiangiogenetic drugs for several treatment options like bone metastasis or osteoporosis. There are several treatment options studied in scientific literature, and one of them with promising results is using platelet concentrates adjunct to surgical therapy. The aim of this study is to examine the therapeutic effect of leukocyte and platelet-rich fibrin (L-PRF) on patients with MRONJ. This 2-centered study investigated patients referred to oral and maxillofacial surgery departments of 2 university clinics between the years 2014 and 2020 with the diagnosis of MRONJ. Demographic data, the indication of the drug usage, drug type, duration, administration route, and systemic comorbidities of the patients were recorded. L-PRF was applied to 20 osteonecrotic lesions of 19 patients following surgical debridement. The male/female ratio was 5/14. Except 1 of the patients, all of the indications of medication were neoplasia-related. The mean follow-up period of patients was 27.9 & PLUSMN;9.2 months. Most common antirezorptive drug was zoledronate (84.2%). Complete resolution was observed in 16 necrosis sites (80%). It could be concluded that the use of L-PRF may represent an important adjunct in the surgical management of MRONJ.en_US
dc.identifier.citation2
dc.identifier.doi10.1097/SCS.0000000000009161
dc.identifier.endpage1044en_US
dc.identifier.issn1049-2275
dc.identifier.issn1536-3732
dc.identifier.issue3en_US
dc.identifier.pmid36627754
dc.identifier.scopus2-s2.0-85159292957
dc.identifier.scopusqualityQ3
dc.identifier.startpage1039en_US
dc.identifier.urihttps://doi.org/10.1097/SCS.0000000000009161
dc.identifier.urihttps://hdl.handle.net/20.500.14517/1236
dc.identifier.volume34en_US
dc.identifier.wosWOS:001012652600091
dc.identifier.wosqualityQ4
dc.institutionauthorCakir M.
dc.language.isoen
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbisphosphonateen_US
dc.subjectdenosumaben_US
dc.subjectL-PRFen_US
dc.subjectMRONJen_US
dc.subjectosteonecrosisen_US
dc.subjectautologous platelet concentratesen_US
dc.subjectsurgical debridementen_US
dc.titleUse of Leukocyte-rich and Platelet-rich Fibrin (L-PRF) Adjunct to Surgical Debridement in the Treatment of Stage 2 and 3 Medication-Related Osteonecrosis of the Jawen_US
dc.typeArticleen_US
dspace.entity.typePublication
relation.isAuthorOfPublication6ed2d0c2-68d1-4a01-a26e-81bd76ca1ab3
relation.isAuthorOfPublication190e5f69-3ae7-4324-a0a2-bff28498e167
relation.isAuthorOfPublication569f6281-7cf0-4d81-8f8d-887f1e3d4a15
relation.isAuthorOfPublication.latestForDiscovery6ed2d0c2-68d1-4a01-a26e-81bd76ca1ab3
relation.isOrgUnitOfPublication9d7f58b2-6caf-4591-83fc-e79c39a149f4
relation.isOrgUnitOfPublication.latestForDiscovery9d7f58b2-6caf-4591-83fc-e79c39a149f4

Files